Enzalutamide and Survival in Nonmetas... - Advanced Prostate...

Advanced Prostate Cancer

22,290 members27,988 posts

Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer in patients with PSADT <10 months.

tango65 profile image
7 Replies

Mean overall survival was 67 months.

"Enzalutamide was associated with a delay in the

use of a new subsequent antineoplastic therapy (hazard ratio for the use of any subsequent antineoplastic therapy, 0.29; 95% CI, 0.25 to 0.35) (Fig. S2A).

The median time to first use of new antineoplastic therapy was 66.7 months in the enzalutamide group and 19.1 months in the placebo group. "

sci-hub.tw/https://www.nejm...

Written by
tango65 profile image
tango65
To view profiles and participate in discussions please or .
Read more about...
7 Replies
GP24 profile image
GP24

I prefer local treatments. "After a median follow-up of 51 months, the 5-year overall survival was superior with stereotactic ablative body radiotherapy (SABR) compared with palliative standard of care (42% vs 18%; P = .006)." practiceupdate.com/C/101811...

GP24 profile image
GP24 in reply toGP24

Here is a study which reports a benefit when treating metastases in CRPC:

sciencedirect.com/science/a...

Schwah profile image
Schwah in reply toGP24

I hope to see Tall Allen chime in here. To date he has been reluctant to acknowledge treatment of mets as life prolonging. This study seems to indicate it does.

Schwah

GP24 profile image
GP24 in reply toSchwah

Schwah,

in the conclusion, the second study I mentioned does not refer to overall survival because the study is not designed to make a definite answer on this question. The authors write:

"MDT [metastasis-directed therapy] appears to have favorable clinical results, prolongs the efficacy of current systemic therapy, and may improve outcomes over treatment with change in systemic therapies alone."

Regarding overall survival the following result [based on two years!] is mentioned in the study:

"In order to assess the impact of MDT + systemic therapy relative to change in systemic therapy alone, we compared outcomes of 31 patients treated with SABR at Johns Hopkins Hospital with those of a cohort of 52 patients treated at the same institution who received a change in systemic therapy alone at the time of progression."

Based on this comparison they found:

"Two year OS was 90.30% for those treated with MDT and 76.80% for those treated with systemic therapy only (p = 0.46)"

I think the study indicates that adding local therapy, e.g. radiation of the mets, to systemic therapy is likely to improve the clinical outcomes for a patient. So you may add this treatment if you think it may help you.

pjoshea13 profile image
pjoshea13

There is no doubt that Enza will tighten the screws when the treatment target is the AR axis. The downside is that treatment-emergent adaptations involving the AR axis are more difficult to manage than the more familiar AR-adaptations to classic ADT.

So, if we followed the study until all off the men were dead, I would expect the mortality curve to have become steeper than the in placebo arm. I think that we might be unimpressed with overall survival. If you look at chart A, the curves are getting closer to each other & perhaps about to cross over.

I wonder what distinguishes the men who died early from the men who made it past 6 years? There was (oddly) no Enza advantage in the first 18 months, but an 11 month advantage had developed by 5 years. & then the advantage appears to shrink.

-Patrick

tango65 profile image
tango65 in reply topjoshea13

Thanks for you comments. I totally agree with your comments.

I wonder how long it took to the patients to die when enza failed. The median time to require other therapy was 67 months , the same than the overall survival. I wonder if this means than when enza fails the cancer is very difficult to control.

Kevinski65 profile image
Kevinski65

I’m 10 years out on enza

Not what you're looking for?

You may also like...

enzalutamide (XTANDI®, Astellas Pharma Inc.) for patients with metastatic castration-sensitive prostate cancer (mCSPC).

On December 16, 2019, the Food and Drug Administration approved enzalutamide (XTANDI®, Astellas...
Darryl profile image
Partner

Olaparib for Metastatic Castration-Resistant Prostate Cancer

TAKE-HOME MESSAGE •In this phase III study, 387 patients with metastatic castration-resistant...
Balsam01 profile image

more possibilities after exhausting SOC?: Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions

Onco Targets Ther. 2018; 11: 7353–7368. Published online 2018 Oct 24. doi: 10.2147/OTT.S153764...
JLS1 profile image

Statin use and survival in metastatic castration-resistant PCa treated with abiraterone or enzalutamide after docetaxel failure.

New study below [1]. I believe that in the U.S. more than half of men my age are using a statin....
pjoshea13 profile image

Androgen Cycling Shows Promise in Castration-Resistant Prostate Cancer

"Following disease progression with abiraterone (Zytiga), treatment with bipolar androgen therapy...
snoraste profile image